Prohost Biotech - Exclusive Biotech Research ~ A Comprehensive Resource for Biotech News

Gilead Sciences Could Acquire Immunomedics at $20 Billion. See Also: AstraZeneca Vaccine Trial Resumed

September 12, 2020 0

Gilead Sciences News Is Not Just Gossip Real news, not just gossip, is spreading today about Gilead Sciences (GILD) nearing a deal to acquire the biotech firm Immunomedics (IMMU) for $20 billion. Immunomedics current market value is around $10 billion which means that Gilead is buying it at double its value. The deal could be announced on Monday, if not …

Sanofi and GlaxoSmithKLine COVID-19 Vaccines are Advancing in Clinical Trial

The U.S. CDC Tells the 50 States to Prepare for...

Kazia Therapeutics Product Paxalisib Beats Temozolomide in Overall Survival in...

Inovio: Good News About the Firm’s COVID-19 Vaccine’s Capability and...

TCR2 Therapeutics Encouraging Oncology Results

Jazz Pharmaceuticals: A New FDA Approval

INmune Bio: A Novel Approach Towards Treating Alzheimer’s Disease

Akero Therapeutics’ Product Efruxifermin Demonstrates Strong Positive Results in NASH...

Celldex Therapeutics: The Beginning of the Firm’s Resurrection

A Potential Merger Between AstraZeneca Plc and Gilead Sciences?

Navidea Biopharmaceuticals: Why This Small Firm’s Stock Skyrocketed

Moderna: Positive Interim Phase 1 Data for its mRNA-1273 Vaccine...

Sorrento Therapeutics: STI-1499 ~ An Encouraging Anti-SARS-CoV-2 Antibody

Alexion Pharmaceuticals to Acquire Portola at $18 Per Share

Moderna: Speeding down the Road Towards Developing a Prophylactic Vaccine...

Compugen: A New Important Patent from Europe and Much More

Why Gilead’s and Moderna’s Stocks Rallied Today

Compugen: A Small Firm with Giant Technological Capabilities

Its All About Coronavirus

Impacting News

Revolution Medicines Inc Has Revolutionary News

September 25, 2020 0

Revolution Medicines Inc Revolution Medicines (RVMD) is a clinical-stage precision oncology company focused on developing targeted …

Amgen’s KRAS G12C Inhibitor Product Sotorasib Has Thrilling Results

September 25, 2020 0

Amgen and the KRAS G12C Protein Discovery The RAS gene family has been a subject for four decades …

Eli Lilly Neutralizing Antibody LY-CoV555 Promises a Reduction in the Rate of COVID-19 Hospitalizations

September 16, 2020 0

Eli Lilly and AbCellera Collaboration Result LY-C0V555 A lot of discoveries, followed by thorough experimentation beyond …

Agenus Stock Rallied Yesterday

September 11, 2020 0

Why Agenus Stock Rallied Yesterday On September 2, 2020 we posted an article about Agenus (AGEN) …

From Inovio: Thermo Fisher Scientific Will Manufacture the Inovio COVID-19 Vaccine Candidate

September 9, 2020 0

Inovio COVID-19 Vaccine Candidate Will be Manufactured by Thermo Fisher Scientific Thermo Fisher Scientific (TMO) joins …

Moderna Inc Stock is Tanking After Rallying

September 1, 2020 0

Moderna Inc Late August Announcements On August 28, 2020 Moderna Inc (MRNA) issued a press release …

Trick or Trade

Agenus: Could It Be a Resurrection? See Also: Prohost Performing Stocks

September 2, 2020 0

Agenus Announced Data from Phase 2 Trials of Balstilimab Agenus (AGEN) immuno-oncology company announced that data …

What’s Going on with Gene Therapy?

August 25, 2020 0

Recent Gene Therapy News On August 20, 2020 Audentes Therapeutics, which was taken over by Astellas …

The FDA’s Complete Response Letters, Creating Investment Opportunities?

August 20, 2020 0

Yesterday, under Today’s Highlights, we posted that the U.S. FDA issued a Complete Response Letter (CRL) …

An Important Announcement from Sorrento Therapeutics

August 13, 2020 0

Sorrento Therapeutics Announcement Sorrento Therapeutics (SRNE) announced that it believes it has uncovered fraudulent attempts to …

Monopar Therapeutics: A Plan for a Test that Predicts COVID-19 Patients Who Might Likely Develop Severe Respiratory Failure

August 13, 2020 0

A Predictive COVID-19 Test? COVID-19 infected people are not all affected to the same degree with …

Alterity Therapeutics: Treating Neurodegenerative Diseases?

August 5, 2020 0

When a small firm’s stock price soars, and more than doubles, curiosity pushes us to investigate. …

Today’s Highlights

The EMA Granted PRIME Designation to CRISPR Therapeutics’ and Vertex Pharmaceuticals’ Product CTX001™ for Severe SCD

September 22, 2020 0

Crispr Therapeutics and Vertex Pharmaceuticals CTX001 Granted PRIME Designation by the EMA CRISPR Therapeutics (CRSP) and …

Seattle Genetics: Two New Oncology Collaborations with Merck

September 14, 2020 0

Seattle Genetics Two New Strategic Oncology Collaborations with Merck Seattle Genetics (SGEN) and Merck (

Cassava Sciences Promising and Encouraging Results of Its Alzheimer’s Disease Product Sumifilam

September 14, 2020 0

Cassava Sciences Study Results of Sumifilam for Alzheimer's Disease Prohost is happy to inform our subscribers …

Compugen Has Encouraging News

September 8, 2020 0

Compugen Announced Encouraging News from Its Phase 1/2 Study of COM701 Compugen (CGEN) announced that the …

Exelixis Announces Submission of sNDA to U.S. FDA for Cabozantinib in Combination with Nivolumab for Advanced RCC

August 25, 2020 0

Exelixis Announces Submission of sNDA to US FDA for CABOMETYX® Exelixis (EXEL) announced the submission of …

Gilead Sciences: An FDA Complete Response Letter Will Not Stop This Firm from Rallying

August 19, 2020 0

Gilead Sciences Was Issued a CLR from the FDA for Filgotinib Gilead Sciences (GILD) is in …

The Week in Review

Questions & Answers

May 27, 2020 0

The Week in Review #51 Questions & Answers About CytomX Q: Is there any reason for …

The World Focus is on COVID-19 Treatments and Vaccines

April 20, 2020 0

The Week in Review #50 The World FOCUS is COVID-19 The world FOCUS right now is …

Stars Before the Coronavirus Outbreak and Those Firms Treating COVID-19

March 24, 2020 0

The Week in Review #49 The Stars from the Weeks Preceding the Novel Coronavirus Outbreak Forty …

The Week in Review #48 ~ Holiday Edition

December 27, 2019 0

The Week in Review #48 Holiday Edition ******************** Merry Christmas and Happy Hanukkah! We Wish You …

What A Week For Biotechnology

November 11, 2019 0

The Week in Review #47 What A Week For Biotechnology Synopsis In this “Week in Review” …

The Quarterly Financial Results

November 4, 2019 0

The Week in Review #46 The Quarterly Financial Results The quarterly financial results that analysts and …

Prohost Letters

Are We Saying Goodbye to Common Sense?

July 3, 2020 2

Prohost Letter #441 Biotechnology Companies’ Evaluations Are We Saying Goodbye to Common Sense? The SARS-CoV-2 Vaccines …

Novel Coronavirus: The Therapeutics

May 11, 2020 0

Prohost Letter #440 Coronavirus The Therapeutics Gilead’s Remdesivir Treating COVID-19 patients requires therapeutic products that can …

Prohost Letter #439

February 19, 2020 0

Prohost Letter #439 The Coronavirus Outbreak - COVID-19 The news announced that the coronavirus (now known …

Prohost Letter #438 ~ The End of the Year Issue 2019

January 1, 2020 0

Prohost Letter #438 End of the Year Issue 2019 Happy New Year 2020 The NASDAQ reached …

An All Time High Market

November 23, 2019 0

Prohost Letter #437 An All Time High Market More Prohost Picks Have Reached the 2019 Targets …

What Are We Experiencing Now?

October 4, 2019 0

Prohost Letter #436 What Are We Experiencing Now? The bizarre market underperformance progressing rather than regressing …